C atheter ablation (CA) of ventricular tachycardia (VT) has proved to be an effective strategy to achieve short-term electric stability in patients with structural heart disease; however, VT recurrences are not uncommon. [1] [2] [3] [4] In patients with ischemic cardiomyopathy (ICM), recurrent sustained VTs may provoke ischemia in areas of critically reduced microvascular perfusion, leading to cell necrosis and replacement fibrosis. Evidences of elevated serum troponin after supraventricular and VTs suggest myocytes death even in the absence of coronary artery disease. 5, 6 A recurrent VT itself may change the electrophysiological properties of the myocardium, predisposing the occurrence and stabilization of new VT re-entry circuits in nonhomogeneous tissue. 7
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In VTACH (Catheter Ablation of Stable Ventricular Tachycardia Before Defibrillator Implantation in Patients With Stable Coronary Heart Disease) trial, CA performed after the first episode of sustained VT of ischemic origin was associated with a prolonged time to VT recurrence. 8 A small retrospective study suggested that earlier referral for VT ablation had superior 1-year VT-free survival compared with delayed ablation. 9 In addition, animal experiments revealed early formation of arrhythmogenic substrate after induced myocardial infarction and suggested better outcomes after immediate ablation. 10, 11 We hypothesized that the arrhythmia substrate evolves in the time, partially driven by the VT itself. Therefore, we aimed to determine whether CA in earlier stages of ventricular remodeling may improve the outcomes, compared with VT ablation performed as a treatment of last resort in patients with advanced stage structural heart disease.
documented sustained VT and to calculate the time from the first VT occurrence to the first CA. Depending on this, patients were divided into 3 groups: early ablation strategy (group 1), consisting of patients ablated within 30 days after the first documented VT; delayed ablation strategy (group 2), patients ablated between 1 month and 1 year after the initial VT; very late ablation strategy (group 3), CA was performed >1 year after the first documented VT.
Because of the differences in the VT-burden all patients were further divided into 2 subgroups. The high VT-burden group consisted of patients referred for CA because of (1) electrical storm, (2) incessant VTs, or (3) >5 VTs, requiring implantable cardioverter defibrillator (ICD) therapies, inclusive shocks in the past 6 months before ablation. 12 The low VT-burden group consisted of patients (1) referred for CA because of recurrent VTs terminated through antitachycardia pacing (ATP) or a single ICD shock or (2) without an ICD, requiring external defibrillation, but in sinus rhythm at the time of hospitalization.
CA Procedure
All patients signed an informed consent before the CA and were prepared according to the clinical routine of our institution. The procedure was performed under conscious sedation. A transseptal puncture using a steerable introducer (Agilis, St. Jude Medical, St. Paul, MN) was performed to access the left ventricle. After entering the left ventricular cavities, heparin was administered to maintain an activation clotting time of over 300 seconds. In cases with suspected epicardial VT, a subxyphoid puncture was performed before the transeptal puncture to avoid inadvertent bleeding complications.
Catheter mapping was facilitated by fluoroscopy in combination with electroanatomic mapping systems (Carto 3 or Carto-RMT, Biosense Webster Inc, CA, or EnSite NavX, St. Jude Medical Inc, St. Paul, MN). In patients in sinus rhythm, we performed voltage maps. Areas with peak-to-peak amplitudes <0.5 mV were defined as scar and areas demonstrating local bipolar electrograms ≥1.5 mV were defined as healthy. All fragmented, late potentials, and appropriate pace mapping sites were annotated. In patients with hemodynamically stable VTs, activation and entrainment mapping were performed to localize the exit sites and critical isthmuses. Radiofrequency energy was delivered using open-irrigated tip catheters (Navistar Thermocool or Navistar Thermocool-RMT, Biosense Webster Inc, Diamond bar, CA) with power settings of ≤50 W and irrigation rates of ≤30 mL/ min. In cases where Coolflex catheters (St. Jude Medical Inc, St. Paul, MN) were used, the irrigation rate was reduced to 17 mL/min.
After the CA, programmed electric stimulation from right ventricular apex and outflow tract was used to assess the procedure success. We used 4 different drive cycle lengths (500, 430, 370, and 330 ms) and introduction of ≤3 extrastimuli until the ventricular refractory period or coupling interval of 200 ms was reached. Ablation of the clinical VT only, determined from the available ECGs and electrogram recordings, was defined as partial success. Noninducibility of any clinical or nonclinical monomorphic sustained VT at the end of the procedure was defined as complete success. 13 After ablation, the antiarrhythmic drugs (AADs) were usually discontinued in cases of complete VT noninducibility. In cases of partial success or failure, the AAD therapy was maintained with the majority of patients receiving amiodarone.
Patient Follow-Up
After the ablation procedure, all patients were monitored continuously until hospital discharge. Patients without ICDs at admission received ICD devices before discharge. Patients with preserved ejection fraction (EF) and noninducible VTs after ablation received implantable loop recorders. After discharge, patients were evaluated in our pacemaker/ICD outpatient clinic at 3-month intervals and in cases of ICD shock delivery.
Primary end points of the study were (1) the recurrence of sustained VT as documented by ICD/implantable loop recorder interrogation and (2) the occurrence of cardiac death. The secondary end points were acute success and procedure-related complications. The follow-up for the clinical events (VT recurrence and mortality) was limited to 2 years. All patients completed the follow-up.
Statistical Analysis
For the continuous variables with normal distribution, the mean values and SDs are reported. For variables with skewed distribution, nonparametric tests were used to compare the groups. For categorical Continuous variables are presented as mean (±SD) and median (IQR). Categorical variables are presented as numbers and proportions. AAD indicates antiarrhythmic drugs; ICD, implantable cardioverter defibrillator; ICM, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and VT, ventricular tachycardia. December 2014 variables, absolute numbers and proportions are used. Student t test, 1-way ANOVA, χ 2 test, and Fischer exact test were used to compare differences across different groups. Event-free survival was estimated by the Kaplan-Meier method, and log-rank statistics was used to compare the groups. The potential confounders were subsequently entered into the Cox proportional hazard model based on univariable association (2-sided P<0.20) and known clinical relevance. Multivariable Cox regression analysis was used for identifying significant predictors of VT recurrence and cardiac mortality while controlling for the relevant covariates. All tests were 2-sided and P value of <0.05 was considered statistically significant. The statistical analysis was performed using SPSS 17.0 (IBM, Armonk, NY).
Results

Baseline Characteristics
Three hundred patients (of them 262 were men; mean age, 65±12 years) with ICM or NIDCM were included in the study.
ICM was the underlying cause in 204 (68%) patients. Fortyseven (15.7%) patients had no ICD at the time of admission and ablation was performed because of VT recurring after ≥1 external defibrillation. At the time of admission, 37 (12.3%) patients had incessant VT, 119 (39.7%) had experienced electrical storm, and 168 (56%) had experienced ≥1 ICD shock. Seventy-five patients (25%) were classified as early ablation (group 1). Eighty-four (28%) patients were allocated to delayed ablation group (group 2). One hundred and forty-one patients (47%) underwent a very late VT ablation (group 3). At admission, 133 (44.3%) patients were on AAD, of them 27 (36%) patients in group 1, 36 (42.9%) patients in group 2, and 70 (49.6%) patients in group 3 (P=0.43). Most of them (117; 39%) were treated with amiodarone: 23 (30.7%) patients in group 1, 32 (38.1%) in group 2, and 62 (44%) in group 3 ( Table 1) . 
... 
Inhospital
Impact of Time to Referral for Ablation on Acute Procedural Outcomes: Complications and Inhospital Mortality
Among 300 patients, 268 (89.3%) were ablated endocardially and 32 (10.7%) patients were ablated both endo-and epicardially. Median of 2 VT (interquartile range [IQR], 2) per patient was induced and targeted for ablation. Acute complete success was achieved in 231 (77.3%) patients. Partial success was additionally achieved in 50 (16.6%) patients.
Patients in group 1 had significantly better left ventricular EF, lower VT-burden, and lower number of VTs inducible using programmed electric stimulation. Complete acute success was achieved in 66 (88.0%) patients in group 1, 68 (81%) cases in group 2, and in 99 (70.2%) patients in group 3 (P=0.008). Partial success was achieved in 8 (10.7%) patients in group 1, 12 (14.3%) patients in group 2, and in 29 (20.6%) patients in group 3 (P=0.14). Procedure failure was observed in 1 (1.3%) patient in group 1, 4 (4.8%) patients in group 2, and in 13 (9.2%) patients in group 3 (P=0.057). Inhospital death occurred in 5 patients (6.7%) in group 1, 2 patients (2.4%) in group 2, and 4 patients (2.8%) in group 3 (P=0.28). Procedure-related complications were observed in 3 patients (4.0%) in group 1, 6 patients (7.1%) in group 2, and 10 patients (7.1%) in group 3 (P=0.63).
After hospital discharge, 100 (33.3%) patients received AAD, 18 (24%) patients in group 1, 27 (32.1%) patients in group 2, and 55 (39%) patients in group 3 (P=0.31). Most patients (83; 27.7%) were treated with amiodarone: 17 (20.5%) patients in group 1, 21 (25.3%) cases in group 2, and 45 (31.9%) patients in group 3. Baseline procedural and postprocedural characteristics are presented in Table 2 .
Impact of Time to Referral for Ablation on VT Recurrence
During 2 years of follow-up, VT recurrence occurred in 28 (37.3%) patients in group 1, in 52 (61.9%) patients in group 2, and in 91 patients (64.5%) in group 3 (P<0.0001).
In univariable analysis, delayed and very late referral for ablation, presence of NIDCM, VT noninducibility at the beginning of the procedure, absence of β-blocker therapy, and failure to eliminate all inducible VTs were predictors of VT recurrence ( Table 3 ). The probability for VT-free survival was significantly higher in the group 1 as compared with group 2 (HR, 1.85 for 2 versus 1; P=0.009) and group 3 (HR, 2.04 for 3 versus 1; P=0.001; Figure 1 ).
In the multivariable analysis after adjustment for age, sex, ICM, arterial hypertension, NYHA class, coronary artery bypass grafting, VT-burden, EF, number of inducible VTs, and mapping approach, use of β-blockers and amiodarone after ablation, and acute complete success, delayed and very late referral for ablation (HR, 1.95 for 2 versus 1; P=0.007 and HR, 1.96 for 3 versus 1; P=0.004), was independently associated with VT recurrence. In addition, the absence of β-blocker therapy (HR, 1.77; P=0.033), prior coronary artery bypass grafting operation (HR, 1.48; P=0.04), and persistent VT inducibility (partial success or ablation failure; HR=1.54; P=0.032) were associated with VT recurrence ( Table 3 ).
Impact of Time to Referral for Ablation on the Cardiac Mortality
Twelve patients (16%) in group 1, 12 (14.3%) patients in group 2, and 26 (18.4%) patients in group 3 died during the follow-up period (P=0.71). In the multivariable analysis after adjustment for age, sex, ICM, arterial hypertension, diabetes mellitus, NYHA class, EF, atrial fibrillation, VT-burden, coronary artery bypass grafting, number of VTs, procedure time, therapy with amiodarone, β-blockers, acute complete success, and VT recurrence, the early ablation strategy was not associated with improved survival (Figure 2 ). The older age (HR, 1.04; P=0.02), lower EF (HR, 0.97; P=0.046), VT recurrence (HR, 2.3; P=0.021), and the absence of β-blocker (HR, 2.69; P=0.031) were the only predictors for cardiac mortality (Table 4 ).
Subgroup Analysis of the Impact of Time to Ablation on VT Recurrence
The high VT-burden group consisted of 171 patients (57%) and the low VT-burden group consisted of 129 patients (43%). In the low VT-burden population, the probability for VT recurrence was significantly higher in group 3 (very late ablation) and 2 (delayed ablation) as compared with group 1 (early ablation; HR, 1.91 for 2 versus 1; P=0.038 and HR, 2.22 for 3 versus 1; P=0.013). On the contrary, in the high VT-burden population, a significant difference in the VT recurrence could not be demonstrated, although there was a tendency for more VT recurrence in groups 2 and 3 (HR, 1.71 for group 2 versus 1; P=0.14 and HR, 1.80 for group 3 versus 1; P=0.078). In addition, differences in the probability of VT recurrence between groups 2 and 1, as well as between groups 3 and 1, were observed in both ICM and NIDCM, only in men, and in patients with EF ≤35%.
Time to Ablation in Relation to Outcomes After CA
In patients with complete success, median time from the first documented VT to ablation was 9 (IQR, 46) months, as compared with 31 (IQR, 80) months in patients with partial success (P=0.001). There was no significant difference in the time to ablation between patients who had procedure-related complications and those who did not: 11 (IQR, 53) months versus 12 (IQR, 53.5) months, respectively (P=0.99). The time from the first documented VT to ablation was 6 (IQR, 45.5) months in patients without VT recurrence, as compared with 19 (IQR, 60) months in patients with VT recurrence (P=0.005). There was no significant difference in the time to ablation between patients who died and the survivors: 16 (IQR, 59) months versus 12 (IQR, 53) months, respectively (P=0.53; Figure 3 ).
Discussion
Up until now, limited data on the appropriate timing for VT ablation have been available with only 2 prospective studies suggesting benefits from earlier ablation in patients with coronary artery disease. 8, 14 Because of its complexity, VT ablation is usually performed in high-volume centers, in patients with high arrhythmia burden and after failure to achieve effective suppression of the VT using AAD. 15 That is why, the majority of the patients experiencing VTs are referred relatively late for CA. However, recent studies in animals and humans demonstrated that the electroanatomic substrate for VT develops early after myocardial infarction. 10, 16 In our study, we observed that patients referred for VT ablation within 30 days after the first documented VT had higher acute success rates compared with patients who underwent ablation later, with similar complications and inhospital mortality rates. This may suggest that the early CA, performed within 30 days after the first documented VT, was not only as safe as the more conservative and delayed CA strategies but also associated with improved acute outcomes. Previously, Frankel et al 9 reported on higher procedural success in patients ablated within 30 days after first documented VT, as compared with those ablated later. However, the differences were not statistically significant, because of either the much lower number of patients included in the study or the higher number of repeated procedures per patient. The observed improved acute success rates in earlier ablated patients can be explained by the lower number of inducible VTs per patient, the better left ventricular EF, and lower VT-burden, suggesting less arrhythmogenic substrate in these patients.
In the study, the long-term outcomes after early VT ablation were significantly better as compared with the outcomes after delayed VT ablation. This observation is in accord with the findings of the VTACH trial, where CA after the first tolerated VT was associated with prolonged time to VT recurrence. 8 In the SMASH (Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia) VT trial, early ablation after the first ICD shock led to a reduction in the ICD shocks afterward. 14 Interestingly, the long-term benefit from CA was observed only in group 1, but not in groups 2 and 3, suggesting lack of additional benefit if the procedure was performed later than 30 days after the first documented VT. In addition to the time to ablation referral, VT of ischemic origin, β-blocker therapy, and successful elimination of all inducible Figure 3 . Showing the median, interquartile range (Q3-Q1) and range for time from first ventricular tachycardia (VT) to ablation, depending on the acute outcome, complications, VT recurrence, and cardiac mortality. The time from the first VT to catheter ablation was significantly shorter in patients with complete success and without VT recurrence. 15 demonstrated that patients with hemodynamically well-tolerated VTs, better EF, and absence of major comorbidities had better VT-free survival, provided a complete VT noninducibility was achieved. These findings, along with our observations, suggest that successful CA performed as a first-line therapy in earlier stages of cardiac remodeling may improve VT-free survival. An important novel finding in the study was that time to CA referral was associated with favorable long-term outcomes not only in patients with ICM but also in those with NIDCM. Considering the higher rates of VT recurrence in NIDCM, an earlier referral for CA can possibly improve the long-term outcomes in these patients. 4 A concern in our study design was the influence of VT-burden on the long-term outcomes because patients with electrical storm, incessant VTs, or frequent ICD shocks may be referred earlier for CA and thus may experience a preferential selection bias. Consequently, we performed a subgroup analysis separately for the low and high VT-burden patients. The benefits of early ablation were attenuated in the high VT-burden group, but remained significant in the subgroup with lower VT-burden. We suggested that this discrepancy may be related to differences in the stage of electroanatomic remodeling, with an earlier and more abundant substrate development in the high VT-burden patients.
Although, early referral for CA was associated with improved acute and long-term procedural outcomes, the cardiac mortality was not influenced by the timing of ablation. This was not an unexpected finding, given that the VTACH study could not demonstrate a reduction in mortality in patients with early VT ablation either. 8 Nevertheless, VT recurrence was an independent predictor of mortality as shown in the Multicenter Thermocool study. 1 Therefore, it is expected that reduction of the VT recurrence through an earlier referral for ablation may result in improved survival at longer follow-up. Further studies, however, are warranted to test this hypothesis.
Two randomized multicenter studies (NCT01576042 and NCT01557842) had been designed to elucidate whether earlier ablation strategy is more effective than medical therapy alone in improving outcomes and reducing mortality in patients with VT of ischemic origin. Given that both have not started yet with patient's recruitment our trial is currently the largest one substantiating the benefits of early CA of VT in both ICM and NIDCM. Our findings may encourage clinicians to refer patients with sustained VTs earlier for CA, especially if the EF ≤35%, and even if they have lower VT-burden. More evidence is necessary to support or renounce the benefits of an earlier ablation strategy. However, this study may serve as the scientific basis for future trials.
Study Limitations
This study is a retrospective analysis of the influence of timing to ablation on the short-and long-term outcomes in patients with VT treated by CA. The large size of the study population with a significant incidence of events allowed for adjustment for many significant and clinically relevant confounders. However, certain residual confounding because of some differences in the baseline characteristics may influence the outcomes. For example, the referral for ablation can be influenced by the severity of the symptoms (incessant VT or electrical storm) and the time of their occurrence. Therefore, we tried to isolate the effects of the VT-burden on the decision for ablation performing subgroup analysis for the patients with low and high VT-burden separately. The results are derived from a high-volume center and may not be directly applicable to low-volume centers without sufficient expertise and welldeveloped facilities for VT ablation. Because most patients already had ICDs implanted before ablation, we could not perform MRI to compare the extent of underlying electroanatomic substrate and correlate it with the outcomes.
Conclusions
CA of scar-related VT performed within 30 days after the first documented VT was safe and associated with better acute success. At 2 years of follow-up, the VT-free survival after early CA was significantly higher; however, no mortality difference was observed. The benefits from earlier CA were observed in patients with low VT-burden and severely depressed left ventricular systolic function.
